Renaissance Capital logo

Amylyx Pharmaceuticals Priced, Nasdaq: AMLX

Phase 3 biotech developing therapies to treat ALS.

Industry: Health Care

Latest Trade: $40.93 0.00 (0.0%)

First Day Return: -4.9%

Return from IPO: +115.4%

Industry: Health Care

Our mission is to develop therapies that change the treatment paradigm for amyotrophic lateral sclerosis, or ALS, and a broad range of neurodegenerative diseases by keeping neurons alive. Unlike most other cells in the body that regularly die and are replaced as part of healthy function, mature neurons are normally resistant to cell death and generally cannot regenerate. We are pursuing commercialization of our product candidate, AMX0035, which we believe is the first drug candidate to show both a functional and survival benefit in a large-scale clinical trial of patients with ALS. We submitted a New Drug Submission, or NDS, in Canada in the second quarter of 2021 for AMX0035 for the treatment of ALS and a New Drug Application, or NDA, to the U.S. Food and Drug Administration, or FDA, in the fourth quarter of 2021. We also intend to submit a Marketing Authorization Application, or MAA, in Europe in the first quarter of 2022. The results of our Phase 2 clinical trial of AMX0035, known as the CENTAUR trial, were published in September 2020 in the New England Journal of Medicine and in October 2020 in the Journal of Muscle and Nerve and demonstrated functional and survival benefits for ALS patients. We believe AMX0035 has the potential to be a foundational therapy, meaning that it could be used alone or in conjunction with other therapies to change the treatment paradigm across a broad range of neurodegenerative diseases.
more less
IPO News for Amylyx Pharmaceuticals
more
IPO Data
IPO File Date 12/16/2021
Offer Price $19.00
Price Range $18.00 - $20.00
Offer Shares (mm) 10.0
Deal Size ($mm) $190
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
IPO Data
IPO Date 01/06/2022
Offer Price $19.00
Price Range $18.00 - $20.00
Offer Shares (mm) 10.0
Deal Size ($mm) $190
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
Underwriters
more
Company Data
Headquarters Cambridge, MA
Founded 2014
Employees 110
Website www.amylyx.com